Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances.

Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances. Abstract Text:

S Bernasconi,F Petraglia,L Iughetti,F Facchinetti,C Marcellini,G Giovannelli,A R Genazzani,

To further evaluate the role exerted by endogenous opioids on LH secretion a naloxone challenge (0.08 mg/Kg b.w. i.v.) was performed in 23 healthy children at different stages of puberty, in 5 adolescents in different period of menstrual cycle, in 3 case of idiopathic precocious puberty (PP), in 7 cases of delayed puberty (DP), in 4 females affected by hypogonadotropic hypogonadism (HH) and in 6 patients affected by polycystic ovary disease (PCOD). Naloxone does not induce any significant change on LH plasma levels in prepubertal healthy children and in all the cases of PP and DP. Similarly there was no LH response in healthy adolescents neither in HH nor in PCOD, the response to naloxone appears only in preovulatory and luteal phases. These data indicate that the central opioid system regulating LH secretion in humans is active only at more advanced stages of puberty and it does not seem to play a role in the beginning of sexual maturation. Moreover gonadal steroids seem to play a fundamental modulatory role on opioid-controlled LH secretion.

Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances. Publishing Authors By Initials

S Bernasconi,F Petraglia,L Iughetti,F Facchinetti,C Marcellini,G Giovannelli,AR Genazzani,

For similar endocrine system diseases: gonadal disorders: puberty, precocious research abstracts see: endocrine system diseases: gonadal disorders: puberty, precocious research

PUBMED ID PMID:

MEDLINE DATE:

Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Acta endocrinologica. Supplementum

VOLUME: 279

Page Numbers: 196-201

Journal Abbreviation:

ISSN: 0300-9750

DAY: 12

MONTH: 02

YEAR: 1986

Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370313

Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances. Keywords Mesh Terms:

KEYWORDS: Puberty, Precocious

MESH TERMS: physiopathology

Chemical & Substance for Abstract: Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances. Information

Substance Name: Luteinizing Hormone

Registry Number: 9002-67-9

Grant and Affiliation Information for Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances.

AFFILIATION:

Country: DENMARK

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Endocrinol Suppl (Copenh)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances Related Publications

• 5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms.
• A case of acro-cephalo-syndactylia [Hebrew text].
• Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
• Brain derived neurotrophic factor circulating levels in patients undergoing IVF.
• Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature.
• CSF beta-EP in headache and depression.
• Calcineurin primes immature gonadotropin-releasing hormone-secreting neuroendocrine cells for migration.
• Characterization of NAD Uptake in Mammalian Cells.
• Circadian variations of proopiocortin-related peptides in children with migraine.
• Click chemistry reactions in medicinal chemistry: Applications of the 1,3-dipolar cycloaddition between azides and alkynes.
• Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: The brain and the vessels.
• Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions.
• Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.
• Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances.
• Endorphin patterns within the headache spectrum disorders.
• Evaluation of central opioid tonus in menstrual migraine.
• Functional hypothalamic amenorrhea: Current view on neuroendocrine aberrations.
• Involvement of serotonin in the central control of opioid secretion.
• Naloxone test in primary headache sufferers.
• Neuroendocrine effects of flunarizine treatment in postmenopausal women.
• Opioid control of the hypothalamus-pituitary-adrenal axis cyclically fails in menstrual migraine.
• P26.08: Bilateral hemorrhagic fetal ovarian cyst: a case report.
• P26.12: Prenatal sonographic features of chloride diarrhea.
• Primary headaches: reduced circulating beta-lipotropin and beta-endorphin levels with impaired reactivity to acupuncture.
• Reduced testosterone levels in cluster headache: a stress-related phenomenon?
• Sympathergic/neuroendocrine reactivity as a marker of adaptive processes underlying migraine susceptibility.
• The association of menstrual migraine with the premenstrual syndrome.
• The management of patients with uterine sarcoma: A debated clinical challenge.
• The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature.
• Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.